A potential role of chondroitin sulfate on bone in osteoarthritis: inhibition of prostaglandin E2 and matrix metalloproteinases synthesis in interleukin-1β- stimulated osteoblasts

Pecchi, Émilie; Priam, Sabrina; Mladenović, Z.; Gosset, Marjolaine; Saurel, Anne-Sophie; Aguilar, L.; Bérenbaum, Francis; Jacques, Claire

doi:10.1016/j.joca.2011.12.002

Cited by 53 publications

(32 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…22,25 The study of extracellular components, such as proteoglycans, fibrous proteins, glycoproteins, metalloproteases, and glycosidases, can shed light on the molecular changes directly related to the development of such diseases. 16,24,26 …”

Section: Discussionmentioning

confidence: 99%

Expression of heparanase in basal cell carcinoma and squamous cell carcinoma

Pinhal

Almeida

Costa

et al. 2016

An. Bras. Dermatol.

View full text Add to dashboard Cite

BackgroundHeparanase is an enzyme that cleaves heparan sulfate chains. Oligosaccharides generated by heparanase induce tumor progression. Basal cell carcinoma and squamous cell carcinoma comprise types of nonmelanoma skin cancer.ObjectivesEvaluate the glycosaminoglycans profile and expression of heparanase in two human cell lines established in culture, immortalized skin keratinocyte (HaCaT) and squamous cell carcinoma (A431) and also investigate the expression of heparanase in basal cell carcinoma, squamous cell carcinoma and eyelid skin of individuals not affected by the disease (control).MethodsGlycosaminoglycans were quantified by electrophoresis and indirect ELISA method. The heparanase expression was analyzed by quantitative RT-PCR (qRTPCR).ResultsThe A431 strain showed significant increase in the sulfated glycosaminoglycans, increased heparanase expression and decreased hyaluronic acid, comparing to the HaCaT lineage. The mRNA expression of heparanase was significantly higher in Basal cell carcinoma and squamous cell carcinoma compared with control skin samples. It was also observed increased heparanase expression in squamous cell carcinoma compared to the Basal cell carcinoma.ConclusionThe glycosaminoglycans profile, as well as heparanase expression are different between HaCaT and A431 cell lines. The increased expression of heparanase in Basal cell carcinoma and squamous cell carcinoma suggests that this enzyme could be a marker for the diagnosis of such types of non-melanoma cancers, and may be useful as a target molecule for future alternative treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Expression of heparanase in basal cell carcinoma and squamous cell carcinoma

Pinhal

Almeida

Costa

et al. 2016

An. Bras. Dermatol.

View full text Add to dashboard Cite

show abstract

“…For instance, Pecchi et al. found that the treatment of IL‐1β inhibited osteoblast maturation by up‐regulating the expression of cyclooxygenase‐2 and metalloproteinase to degrade the extracellular matrix of bone tissue. In contrast, short‐term exposure of IL‐1β promoted nodule formation , and the injection of IL‐1β accelerated endochondral ossification in mice bone fracture .…”

Section: Discussionmentioning

confidence: 99%

Melatonin mediates protective effects on inflammatory response induced by interleukin‐1 beta in human mesenchymal stem cells

Liu

Gong

Xiong

et al. 2013

Journal of Pineal Research

View full text Add to dashboard Cite

Joint diseases like osteoarthritis usually are accompanied with inflammatory processes, in which pro-inflammatory cytokines mediate the generation of intracellular reactive oxygen species (ROS) and compromise survival of subchondral osteoblasts. Melatonin is capable of manipulating bone formation and osteogenic differentiation of mesenchymal stem cells (MSCs). The aim of this work was to investigate the anti-inflammatory effect of melatonin on MSC proliferation and osteogenic differentiation in the absence or presence of interleukin-1 beta (IL-1β), which was used to induce inflammation. Our data showed that melatonin improved cell viability and reduced ROS generation in MSCs in a dose-dependent manner. When exposed to 10 ng/mL IL-1β, various concentrations of melatonin resulted in significant reduction of ROS by 34.9% averagely. Luzindole as a melatonin receptor antagonist reversed the anti-oxidant effect of melatonin in MSCs with co-exposure to IL-1β. Real-time RT-PCR data suggested that melatonin treatment up-regulated the expression of CuZnSOD and MnSOD, while down-regulated the expression of Bax. To investigate the effect of melatonin on osteogenesis, MSCs were cultured in osteogenic differentiation medium supplemented with IL-1β, melatonin, or luzindole. After exposed to IL-1β for 21 days, 1 μm melatonin treatment significantly increased the levels of type I collagen, ALP, and osteocalcin, and 100 μm melatonin treatment yielded the highest level of osteopontin. Our study demonstrated that melatonin maintained MSC survival and promoted osteogenic differentiation in inflammatory environment induced by IL-1β, suggesting melatonin treatment could be a promising method for bone regenerative engineering in future studies.

show abstract

“…23 Hyaluronic acid and chondroitin sulfate are polysaccharides found in the synovial fluid, extracellular matrix, and connective tissue, and have an important role in articular homeostasis. 24,25 In addition, they have anti-inflammatory and anticatabolic properties that attenuate production of inflammatory mediators by chondrocytes, 26 as well as having an analgesic action in arthritic joints. 27 It has also been demonstrated that hyaluronic acid and chondroitin sulfate reduce friction and strain on the articular cartilage.…”

Section: Introductionmentioning

confidence: 99%

Development of biodegradable methylprednisolone microparticles for treatment of articular pathology using a spray-drying technique

Tobar-Grande¹,

Godoy²,

Bustos³

et al. 2013

IJN

View full text Add to dashboard Cite

Abstract:In this work, microparticles were prepared by spray-drying using albumin, chondroitin sulfate, and hyaluronic acid as excipients to create a controlled-release methylprednisolone system for use in inflammatory disorders such as arthritis. Scanning electron microscopy demonstrated that these microparticles were almost spherical, with development of surface wrinkling as the methylprednisolone load in the formulation was increased. The methylprednisolone load also had a direct influence on the mean diameter and zeta potential of the microparticles. Interactions between formulation excipients and the active drug were evaluated by x-ray diffraction, differential scanning calorimetry, and thermal gravimetric analysis, showing limited amounts of methylprednisolone in a crystalline state in the loaded microparticles. The encapsulation efficiency of methylprednisolone was approximately 89% in all formulations. The rate of methylprednisolone release from the microparticles depended on the initial drug load in the formulation. In vitro cytotoxic evaluation using THP-1 cells showed that none of the formulations prepared triggered an inflammatory response on release of interleukin-1β, nor did they affect cellular viability, except for the 9.1% methylprednisolone formulation, which was the maximum test concentration used. The microparticles developed in this study have characteristics amenable to a therapeutic role in inflammatory pathology, such as arthritis.

show abstract

A potential role of chondroitin sulfate on bone in osteoarthritis: inhibition of prostaglandin E2 and matrix metalloproteinases synthesis in interleukin-1β- stimulated osteoblasts

Cited by 53 publications

References 52 publications

Expression of heparanase in basal cell carcinoma and squamous cell carcinoma

Expression of heparanase in basal cell carcinoma and squamous cell carcinoma

Melatonin mediates protective effects on inflammatory response induced by interleukin‐1 beta in human mesenchymal stem cells

Development of biodegradable methylprednisolone microparticles for treatment of articular pathology using a spray-drying technique

Contact Info

Product

Resources

About